Economy/Home · Economy

[Breaking] Gyeongnam Pharmaceutical Withdraws 19.487 Billion Won Paid-In Capital Increase... SK Securities Notifies Termination of Underwriting Agreement

Gyeongnam Pharmaceutical is withdrawing its paid-in capital increase of 19.487 billion won, which it had pursued to secure operating funds. Gyeongnam Pharmaceutical announced on the 12th, through a disclosure on other major management matters and a correction to its paid-in capital increase decisio

Oseong Kwon
Staff Reporter
5 min read
[Breaking] Gyeongnam Pharmaceutical Withdraws 19.487 Billion Won Paid-In Capital Increase... SK Securities Notifies Termination of Underwriting Agreement
CBC News

Gyeongnam Pharmaceutical is withdrawing its paid-in capital increase of 19.487 billion won, which it had pursued to secure operating funds.

Gyeongnam Pharmaceutical announced on the 12th, through a disclosure on other major management matters and a correction to its paid-in capital increase decision, that it would withdraw its decision to conduct a rights offering to issue 13 million registered common shares and would also withdraw the related securities registration statement.

■ Background of the Capital Increase

The capital increase began with a board resolution on May 21. Gyeongnam Pharmaceutical pursued a paid-in capital increase through a rights offering combined with a general public subscription for unsubscribed shares, aiming to raise operating funds. At the time, the initial number of shares to be issued was 11 million, with a planned issue amount of 19.085 billion won.

Subsequently, on September 7, the company submitted a corrected securities registration statement, changing the method to a rights offering and adjusting the number of shares to be issued to 13 million and the planned issue amount to 19.487 billion won.

■ Reasons for the Withdrawal

The company explained that during the public offering process, it continued reviewing revisions to the securities registration statement in response to the Financial Services Commission's request to submit corrected reports. It also stated that as the review schedule for the securities registration statement was prolonged, there was a possibility of some delays in the timing of fundraising and its planned use.

In connection with this, lead manager SK Securities notified the termination of the contract on the 8th pursuant to Article 21, Paragraph 1, Item 21 of the underwriting agreement and related regulations. Accordingly, Gyeongnam Pharmaceutical decided to withdraw its paid-in capital increase decision and the related securities registration statement.

■ Future Plans

Gyeongnam Pharmaceutical emphasized that this withdrawal does not mean a halt to its existing businesses or new product development. Going forward, it plans to comprehensively consider its operating cash flow, financial condition, business progress, and market conditions to re-examine the necessary scale of funds and methods of raising them.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.